All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How does transfusion independence impact survival outcomes with momelotinib in MF?

Jun 15, 2021
Share:

During ASCO and EHA 2021, the MPN Hub spoke with Ruben A Mesa, UT Health San Antonio, San Antonio, US. We asked, How does transfusion independence impact survival outcomes with momelotinib in myelofibrosis (MF)?

How does transfusion independence impact survival outcomes with momelotinib in MF?

Momelotinib is a JAKi that attenuates anemia in patients with MF. Mesa describes an analysis of the SIMPLIFY-1 study, comparing momelotinib with ruxolitinib in the frontline setting, and presents the correlation between transfusion-independent response and overall survival (OS) with momelotinib treatment.


Share: